ReviewCureus2021
Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.
Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- The Implementation Climate for Integrating Buprenorphine Prescribing into Rural Primary Care.Journal of general internal medicine · 2025Article
- Telemedicine to improve access to medications for opioid use disorder in Illinois, 2022-2024.The International journal on drug policy · 2025Article
- Overcoming barriers to traditional care delivery and pharmacy challenges: a qualitative study of buprenorphine, telehealth, and a digital therapeutic for opioid use disorder.Substance abuse treatment, prevention, and policy · 2025Article
- Evaluation of a Program Designed to Support Implementation of Prescribing Medication for Treatment of Opioid Use Disorder in Primary Care Practices.Annals of family medicine · 2025Article
- Medication treatment for opioid use disorder among rural primary care patients.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2024Article
- Biopsychosocial contexts of timely and adequate prenatal care utilization among women with criminal legal involvement and opioid use disorder.BMC public health · 2023Observational
- Impact of Policy Change on Access to Medication for Opioid Use Disorder in Primary Care.Southern medical journal · 2023Article
- Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder.Drug and alcohol dependence reports · 2022Article
- Buprenorphine: A Better Option for Opioid Use Disorder Treatment in Pregnancy Compared to Methadone.Journal of the American Board of Family Medicine : JABFMArticle
- Article
- Access to MAT: Participants' Experiences With Transportation, Non-Emergency Transportation, and Telehealth.Journal of primary care & community healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Buprenorphine/Naloxone (Suboxone®) is an efficacious treatment for opioid use disorder (OUD) due to its more convenient dosing, superior safety profile, and decreased incidence of negative side effects when compared to other forms of medications for opioid use disorder (MOUD). In the United States, updated legislation in 2021 entitled, "The Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder",
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.